The first patient expert training course of the European Patients' Academy (EUPATI) has begun.
The first patient expert training course of the European Patients’ Academy (EUPATI) has begun. The 15-month program is designed to meet the needs of patients and patient representatives and to impart expert knowledge about the whole spectrum of the medicine research and development process.
“The course is specifically designed to meet the needs of participants who are motivated with the skill set to acquire and apply this expert-level knowledge,” said Jan Geissler, EUPATI Director, who noted that earlier this month a webinar marked the official opening of the course and the launch of the online learning program for 53 participants.
The course comprises a mixture of online and face-to-face training and covers discovery, development, evaluation, marketing authorization and post-marketing evaluation, and other important subjects. Participants will take six e-learning modules covering a broad range of topics. They will also attend two face-to-face training events for interactive teaching and have the opportunity to meet directly with other patient experts and with specialists working in the field of medicine development.
The organizers plan to encourage participants to apply knowledge and skills acquired through three main areas:
The second wave of the program will start in September 2015. By 2016, there will be over 100 expert patients who will be able to share their expertise and help to reach the patient community, raise public awareness and generate dialogue around future patient involvement in research and development.
EUPATI received more than 300 applications for the course. An independent evaluation panel selected 53 participants based upon careful examination of all eligible applications against the pre-defined selection criteria. The application period for next year's EUPATI course will start in spring 2015.
Read the full release here.
Truqap Combination Shines in Phase III Trial for Prostate Cancer
November 26th 2024Data from the CAPItello-281 trial show Truqap alongside abiraterone and androgen deprivation therapy achieved a statistically significant and clinically meaningful improvement in radiographic progression-free survival.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.